New diabetes drug semaglutide put to the test in argentine Real-World study

NCT ID NCT07621419

Recruiting now Disease control Sponsor: Hospital Italiano de Buenos Aires Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is tracking 145 adults with type 2 diabetes in Argentina who are starting semaglutide (either as a pill or injection) as part of their normal care. Researchers will measure changes in blood sugar, weight, waist size, and grip strength over 12 months, along with how satisfied patients are with the treatment. The goal is to see how well semaglutide works in real-life settings, not just in tightly controlled clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide (oral and injectable forms)
What this could lead to: If successful, this study could confirm that semaglutide works well in everyday Argentine clinics, helping doctors choose the best treatment for type 2 diabetes.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It is also relatively small (145 people) and only follows patients for one year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus Obesity type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS

Contacts and locations

Locations

Hospital General de Agudos Dr Enrique Tornú
RECRUITING

Buenos Aires, Buenos Aires, 1427, Argentina
Hospital Italiano de Buenos Aires
RECRUITING

Buenos Aires, Buenos Aires, 1199, Argentina

More trials for these conditions

Other studies related to the condition(s) this trial covers.